Cargando…

Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database

BACKGROUND: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). AIMS: To evaluate real-world data in US patients with UC receiving tofacitinib. METHODS: Characteristics and outcomes of patients with UC initiating tofacitinib between 2018 and 201...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiorean, Michael, Ha, Christina, Hur, Peter, Sharma, Puza P., Gruben, David, Khan, Nabeel H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516786/ https://www.ncbi.nlm.nih.gov/pubmed/37639057 http://dx.doi.org/10.1007/s10620-023-08063-4

Ejemplares similares

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
por: Chiorean, Michael V., et al.
Publicado: (2022)

Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
por: Chiorean, Michael V., et al.
Publicado: (2022)

Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
por: Mease, Philip J., et al.
Publicado: (2022)

The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme
por: Farraye, Francis A., et al.
Publicado: (2021)

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
por: Long, Millie D, et al.
Publicado: (2022)

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
por: Curtis, Jeffrey R, et al.
Publicado: (2020)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database
por: Harnett, James, et al.
Publicado: (2016)

The role and prospect of tofacitinib in patients with ulcerative colitis
por: Lee, Jun
Publicado: (2023)

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
por: Loftus, Edward V, et al.
Publicado: (2022)

Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis
por: Wang, Wenfei, et al.
Publicado: (2019)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2018)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Review article: guide to tofacitinib dosing in patients with ulcerative colitis
por: Irving, Peter M., et al.
Publicado: (2022)

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021)

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
por: Lucaciu, Laura A., et al.
Publicado: (2021)

Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries
por: Armuzzi, Alessandro, et al.
Publicado: (2023)

Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management
por: Sands, Bruce E, et al.
Publicado: (2020)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database
por: Seo, Gi Hyeon, et al.
Publicado: (2022)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program
por: Sands, Bruce E, et al.
Publicado: (2021)

Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
por: Long, Millie D, et al.
Publicado: (2020)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
por: Paschos, Paschalis, et al.
Publicado: (2018)

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
por: Sandborn, William J., et al.
Publicado: (2019)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis
por: Bodryagina, Evgenia, et al.
Publicado: (2022)

Fulminant Demodex folliculitis in a patient with ulcerative colitis treated with tofacitinib
por: Neudorfer, Carolina, et al.
Publicado: (2023)

Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program
por: Chiorean, Michael, et al.
Publicado: (2023)

Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data
por: Varyani, Fumi, et al.
Publicado: (2019)

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
por: Shimizu, Hiromichi, et al.
Publicado: (2021)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats
por: Bae, Sung Hun, et al.
Publicado: (2022)

Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
por: Lichtenstein, Gary R., et al.
Publicado: (2023)

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
por: Gil, Fabio, et al.
Publicado: (2022)

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dtrlqcvhbo68rl5fo01ubna0te